Delving into the Latest Updates on Gamma hydroxybutyric with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

opioid dependence methadoneOpioid-Related Disorders

Originator Organization-

Active Organization-

Inactive Organization

National Institute on Drug Abuse

Poitiers University Hospital

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Dear Editor: Use of sodium oxybate (SO) in patients with obstructive sleep apnea (OSA) and narcolepsy is controversial. SO is the firstline treatment for cataplexy in patients with narcolepsy [1]. SO is a derivate of Gamma-hydroxybutyrate (GHB), a natural metabolite of the brainstem. GHB is a short-chain fatty acid, with action as an inhibitory neurotransmitter or neuromodulator. Mamelak [2] observed a decrease in apneahypopnea index (AHI) after treatment with gamma-OH in a patient with central apnea and narcolepsy. Another study performed in patients with OSA did not find differences between AHI before and after gamma-OH treatment [3]. The article published by Dr. Feldman [4], and the recent report of two cases in patients with narcolepsy and OSA who suffered an increase in AHI after SO treatment [5], suggests that sodium oxybate administration should be done under polysomnographic control. We present a 64-year-old man with OSA (obstructive and mixed apneas) and narcolepsy. He has been controlled and treated in our laboratory with Modafinil 300 mg/d, Fluoxetine 20 mg/day and 6.5 cm H2O nasal continuous positive airway pressure (CPAP). At baseline night, body mass index (BMI) was 29.8 Kg/m and AHI was 32.3/h. Since excessive daytime sleepiness and daily cataplexy persisted, we performed a new polysomnography (PSG) with CPAP. Next day, the multiple sleep latency test showed a mean sleep latency of 4.3 min and four sleep-onset rapid eye movement sleep periods. Patient started treatment with SO 4.5 g/night (in two doses), and simultaneously Modafinil and Fluoxetine were gradually withdrawn. One month later, since patient still presented excesive daytime sleepiness and minor cataplexy, we decided to increase SO to 6 g/night and perform a PSG, without CPAP in this case. BMI did not change. PSG showed a 45.1% increase of slow wave sleep and a 40.8% decrease in AHI (from 32.3 to 13.2/h). It is known that most apneic events occur during stages 1 and 2 of non-rapid eye movement (NREM) sleep, and rapid eye movement (REM) sleep, so the decrease of AHI could be due to an increase in slow wave sleep. Whereas in this case, the decrease in AHI was 42.9% during REM and 57.1% during NREM sleep, as reported by Mamelak, so we think that our findings could be due to a greater stability and continuity in sleep produced by sodium oxybate, and its action in decreasing respiratory events with central component and cyclic alternanting pattern related [6]. Prospective studies are necessary to confirm our hypothesis.

01 May 2009·Der NervenarztQ4 · MEDICINE

Schweres Entzugsdelir bei chronischem γ-Hydroxybuttersäure-Konsum

Q4 · MEDICINE

Article

Author: B. Steinacher ; G. Proest ; T. Zschernack ; M. Stelzig

100 Deals associated with Gamma hydroxybutyric

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
opioid dependence methadone	Phase 2	United States	National Institute on Drug Abuse	01 Jan 1993
Opioid-Related Disorders	Phase 2	United States	National Institute on Drug Abuse	01 Jan 1993